Fig_3.tif (3.58 MB)
Axitinib modulates cytokine levels in DCs and impairs T cell stimulatory function of DCs.
figure
posted on 2015-06-04, 03:16 authored by Annkristin Heine, Stefanie Andrea Erika Held, Solveig Nora Daecke, Kati Riethausen, Philipp Kotthoff, Chrystel Flores, Christian Kurts, Peter BrossartMonocytes were cultured under DC-driving conditions and treated with axitinib once on day 5, followed by LPS-activation on day 6. Supernatants were collected on day 7 and analyzed for cytokine production using a commercially available FlowCytoMix Assay. Results of one representative donor out of 3 are shown.
History
Usage metrics
Categories
Keywords
cell carcinomaSTAT 3treatment strategiesfuture vaccination protocolsT cell activationinhibitionlymphocyte reaction assayVEGF receptorallogeneic T cell proliferationdendritic cellactivation markersfactor kappa Bvegfrt cellstranscription factor cRelCD 86.expressionline therapyDC migrationDCs resultsfunctionaxitinibFunction InhibitorsT lymphocytesDC activationDC differentiationp 38
